Category:Screening - Revision history

Bosmana fem: /* Wilson and Jungner Criteria */

2023-07-11T04:37:02Z

Wilson and Jungner Criteria

← Older revision		Revision as of 04:37, 11 July 2023
Line 6:		Line 6:

	# '''The condition sought should be an important health problem.'''		# '''The condition sought should be an important health problem.'''
	#* There should be a clear understanding of the epidemiology of the condition, including incidence and prevalence, and the health and economic burden on individuals and society. The condition should be a significant public health problem justifying the investment in a screening program.		#* There should be a clear understanding of the epidemiology of the condition, including [[Incidence rate\|incidence]] and [[prevalence]], and the health and economic burden on individuals and society. The condition should be a significant public health problem justifying the investment in a screening program.
	# '''There should be an accepted treatment for patients with recognized disease.'''		# '''There should be an accepted treatment for patients with recognized disease.'''
	#* If no treatment or intervention is available that changes the course of the disease, or if the treatment is not generally accepted, then early detection might not lead to improved outcomes.		#* If no treatment or intervention is available that changes the course of the disease, or if the treatment is not generally accepted, then early detection might not lead to improved outcomes.

Bosmana fem: /* References: */

2023-07-11T04:27:42Z

References:

← Older revision		Revision as of 04:27, 11 July 2023
Line 28:		Line 28:

	==References:==		==References:==
			* This text was originally generated on 11 July 2023 by ChatGPT4.0 and reviewed by Arnold Bosman.
	* Wilson, J. M. G., & Jungner, G. (1968). Principles and Practice of Screening for Disease. World Health Organization. Public Health Papers, 34. [This is the seminal work where the criteria were first proposed.]		* Wilson, J. M. G., & Jungner, G. (1968). Principles and Practice of Screening for Disease. World Health Organization. Public Health Papers, 34. [This is the seminal work where the criteria were first proposed.]
	* Andermann, A., Blancquaert, I., Beauchamp, S., & Déry, V. (2008). Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin of the World Health Organization, 86, 317-319. [This paper reviews the criteria and their application in the era of genomic medicine.]		* Andermann, A., Blancquaert, I., Beauchamp, S., & Déry, V. (2008). Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin of the World Health Organization, 86, 317-319. [This paper reviews the criteria and their application in the era of genomic medicine.]

Bosmana fem: /* Wilson and Jungner Criteria */

2023-07-11T04:26:17Z

Wilson and Jungner Criteria

Bosmana fem: /* Wilson and Jungner Criteria */

2023-07-11T04:24:41Z

Wilson and Jungner Criteria

← Older revision		Revision as of 04:24, 11 July 2023
Line 5:		Line 5:


	;# The condition sought should be an important health problem.		# The condition sought should be an important health problem.
	: There should be a clear understanding of the epidemiology of the condition, including incidence and prevalence, and the health and economic burden on individuals and society. The condition should be a significant public health problem justifying the investment in a screening program.		#* There should be a clear understanding of the epidemiology of the condition, including incidence and prevalence, and the health and economic burden on individuals and society. The condition should be a significant public health problem justifying the investment in a screening program.
			# There should be an accepted treatment for patients with recognized disease.
	;# There should be an accepted treatment for patients with recognized disease.		#* If no treatment or intervention is available that changes the course of the disease, or if the treatment is not generally accepted, then early detection might not lead to improved outcomes.
	: If no treatment or intervention is available that changes the course of the disease, or if the treatment is not generally accepted, then early detection might not lead to improved outcomes.		# Facilities for diagnosis and treatment should be available.
			#* Prior to starting a screening program, health systems should ensure there are sufficient resources for diagnostic confirmation and treatment of individuals who screen positive, as well as appropriate follow-up.
	;# Facilities for diagnosis and treatment should be available.		# There should be a recognizable latent or early symptomatic stage.
	: Prior to starting a screening program, health systems should ensure there are sufficient resources for diagnostic confirmation and treatment of individuals who screen positive, as well as appropriate follow-up.		#* This criterion refers to the natural history of the disease. There should be a period during which the disease can be detected before the onset of symptoms, and intervention at this stage should lead to better outcomes.
			# There should be a suitable test or examination.
	;# There should be a recognizable latent or early symptomatic stage.		#* The screening test should be reliable, safe, inexpensive, and valid with high sensitivity and specificity. It should be able to accurately detect the early or latent stage of the disease.
	: This criterion refers to the natural history of the disease. There should be a period during which the disease can be detected before the onset of symptoms, and intervention at this stage should lead to better outcomes.		# The test should be acceptable to the population.
			#* The screening program should be organized in a way that encourages high participation rates. The test should be acceptable to potential participants in terms of comfort, cost, and accessibility.
	;# There should be a suitable test or examination.		# The natural history of the condition, including development from latent to declared disease, should be adequately understood.
	: The screening test should be reliable, safe, inexpensive, and valid with high sensitivity and specificity. It should be able to accurately detect the early or latent stage of the disease.		#* A comprehensive understanding of the disease process is essential, including how the disease progresses from the early or latent stage to symptomatic disease.
			# There should be an agreed policy on whom to treat as patients.
	;# The test should be acceptable to the population.		#* Clear guidelines should be established on who will be treated once a disease is detected through screening, considering factors such as stage of the disease, age, and comorbidities.
	: The screening program should be organized in a way that encourages high participation rates. The test should be acceptable to potential participants in terms of comfort, cost, and accessibility.		# The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole.
			#* A cost-benefit analysis should be performed to determine if the benefits of early detection and treatment through the screening program outweigh the costs.
	;# The natural history of the condition, including development from latent to declared disease, should be adequately understood.		# Case-finding should be a continuing process and not a “once and for all” project.
	: A comprehensive understanding of the disease process is essential, including how the disease progresses from the early or latent stage to symptomatic disease.		#* Screening should be an ongoing, systematic process rather than a one-off project. There should be a commitment to maintaining the program, with regular intervals for repeated screening.

	;# There should be an agreed policy on whom to treat as patients.
	: Clear guidelines should be established on who will be treated once a disease is detected through screening, considering factors such as stage of the disease, age, and comorbidities.

	;# The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole.
	: A cost-benefit analysis should be performed to determine if the benefits of early detection and treatment through the screening program outweigh the costs.

	;# Case-finding should be a continuing process and not a “once and for all” project.
	: Screening should be an ongoing, systematic process rather than a one-off project. There should be a commitment to maintaining the program, with regular intervals for repeated screening.

Bosmana fem: /* Wilson and Jungner Criteria */

2023-07-11T04:23:24Z

Wilson and Jungner Criteria

Bosmana fem: /* Wilson and Jungner Criteria */

2023-07-11T04:22:16Z

Wilson and Jungner Criteria

← Older revision		Revision as of 04:22, 11 July 2023
Line 30:		Line 30:

	;The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole.		;The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole.
	; A cost-benefit analysis should be performed to determine if the benefits of early detection and treatment through the screening program outweigh the costs.		: A cost-benefit analysis should be performed to determine if the benefits of early detection and treatment through the screening program outweigh the costs.

	;Case-finding should be a continuing process and not a “once and for all” project.		;Case-finding should be a continuing process and not a “once and for all” project.

Bosmana fem at 04:21, 11 July 2023

2023-07-11T04:21:45Z

← Older revision		Revision as of 04:21, 11 July 2023
Line 1:		Line 1:
			Public health screening is a vital component of healthcare systems in Europe, aimed at detecting diseases or risk factors in asymptomatic individuals to enable early intervention and improved health outcomes. In the European context, the principles of public health screening are guided by the Wilson and Jungner criteria, established by the World Health Organization (WHO) in 1968, and adapted to the specific needs and objectives of each country within the European Union (EU) and European Economic Area (EEA).

			=Wilson and Jungner Criteria=
			The Wilson and Jungner criteria, first proposed in a 1968 World Health Organization report, provide a set of principles to guide the development and evaluation of screening programs in public health (Wilson & Jungner, 1968). These criteria consider a range of factors, including the importance of the disease in a population, the availability and acceptability of treatment, and the ability to detect the disease early through screening. According to these criteria, a disease should be an important health problem, its natural history should be well understood, and there should be a recognizable early stage of the disease. Additionally, there should be an effective and acceptable treatment, and the cost of case-finding should be balanced against the benefits of disease detection. Screening is not merely about test administration; it involves the integration of screening programs into the healthcare system, ensuring there is a process in place for further diagnostic testing, treatment, and follow-up. The Wilson and Jungner criteria remain a foundational tool in the planning and assessment of public health screening programs.


			;The condition sought should be an important health problem.
			: There should be a clear understanding of the epidemiology of the condition, including incidence and prevalence, and the health and economic burden on individuals and society. The condition should be a significant public health problem justifying the investment in a screening program.

			;There should be an accepted treatment for patients with recognized disease.
			: If no treatment or intervention is available that changes the course of the disease, or if the treatment is not generally accepted, then early detection might not lead to improved outcomes.

			;Facilities for diagnosis and treatment should be available.
			; Prior to starting a screening program, health systems should ensure there are sufficient resources for diagnostic confirmation and treatment of individuals who screen positive, as well as appropriate follow-up.

			;There should be a recognizable latent or early symptomatic stage.
			: This criterion refers to the natural history of the disease. There should be a period during which the disease can be detected before the onset of symptoms, and intervention at this stage should lead to better outcomes.

			;There should be a suitable test or examination.
			: The screening test should be reliable, safe, inexpensive, and valid with high sensitivity and specificity. It should be able to accurately detect the early or latent stage of the disease.

			;The test should be acceptable to the population.
			: The screening program should be organized in a way that encourages high participation rates. The test should be acceptable to potential participants in terms of comfort, cost, and accessibility.

			;The natural history of the condition, including development from latent to declared disease, should be adequately understood.
			; A comprehensive understanding of the disease process is essential, including how the disease progresses from the early or latent stage to symptomatic disease.

			;There should be an agreed policy on whom to treat as patients.
			: Clear guidelines should be established on who will be treated once a disease is detected through screening, considering factors such as stage of the disease, age, and comorbidities.

			;The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole.
			; A cost-benefit analysis should be performed to determine if the benefits of early detection and treatment through the screening program outweigh the costs.

			;Case-finding should be a continuing process and not a “once and for all” project.
			: Screening should be an ongoing, systematic process rather than a one-off project. There should be a commitment to maintaining the program, with regular intervals for repeated screening.


			==References:==

			* Wilson, J. M. G., & Jungner, G. (1968). Principles and Practice of Screening for Disease. World Health Organization. Public Health Papers, 34. [This is the seminal work where the criteria were first proposed.]
			* Andermann, A., Blancquaert, I., Beauchamp, S., & Déry, V. (2008). Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bulletin of the World Health Organization, 86, 317-319. [This paper reviews the criteria and their application in the era of genomic medicine.]
			* Raffle, A. E., Gray, J. A. M. (Eds.). (2007). Screening: Evidence and Practice. Oxford University Press. [This book offers a comprehensive overview of screening, including the use of Wilson and Jungner's criteria.]


	[[Category:Assessing the burden of disease and risk assessment]]		[[Category:Assessing the burden of disease and risk assessment]]

Bosmana fem: Bosmana fem moved page Screening to Category:Screening

2023-03-22T22:24:22Z

Bosmana fem moved page Screening to Category:Screening

← Older revision	Revision as of 22:24, 22 March 2023
(No difference)

Bosmana fem: Created page with " Category:Assessing the burden of disease and risk assessment"

2023-03-22T20:32:38Z

Created page with " Category:Assessing the burden of disease and risk assessment"

New page

[[Category:Assessing the burden of disease and risk assessment]]

← Older revision		Revision as of 04:26, 11 July 2023
Line 5:		Line 5:


	# The condition sought should be an important health problem.		# '''The condition sought should be an important health problem.'''
	#* There should be a clear understanding of the epidemiology of the condition, including incidence and prevalence, and the health and economic burden on individuals and society. The condition should be a significant public health problem justifying the investment in a screening program.		#* There should be a clear understanding of the epidemiology of the condition, including incidence and prevalence, and the health and economic burden on individuals and society. The condition should be a significant public health problem justifying the investment in a screening program.
	# There should be an accepted treatment for patients with recognized disease.		# '''There should be an accepted treatment for patients with recognized disease.'''
	#* If no treatment or intervention is available that changes the course of the disease, or if the treatment is not generally accepted, then early detection might not lead to improved outcomes.		#* If no treatment or intervention is available that changes the course of the disease, or if the treatment is not generally accepted, then early detection might not lead to improved outcomes.
	# Facilities for diagnosis and treatment should be available.		# '''Facilities for diagnosis and treatment should be available.'''
	#* Prior to starting a screening program, health systems should ensure there are sufficient resources for diagnostic confirmation and treatment of individuals who screen positive, as well as appropriate follow-up.		#* Prior to starting a screening program, health systems should ensure there are sufficient resources for diagnostic confirmation and treatment of individuals who screen positive, as well as appropriate follow-up.
	# There should be a recognizable latent or early symptomatic stage.		# '''There should be a recognizable latent or early symptomatic stage.'''
	#* This criterion refers to the natural history of the disease. There should be a period during which the disease can be detected before the onset of symptoms, and intervention at this stage should lead to better outcomes.		#* This criterion refers to the natural history of the disease. There should be a period during which the disease can be detected before the onset of symptoms, and intervention at this stage should lead to better outcomes.
	# There should be a suitable test or examination.		# '''There should be a suitable test or examination.'''
	#* The screening test should be reliable, safe, inexpensive, and valid with high sensitivity and specificity. It should be able to accurately detect the early or latent stage of the disease.		#* The screening test should be reliable, safe, inexpensive, and valid with high sensitivity and specificity. It should be able to accurately detect the early or latent stage of the disease.
	# The test should be acceptable to the population.		# '''The test should be acceptable to the population.'''
	#* The screening program should be organized in a way that encourages high participation rates. The test should be acceptable to potential participants in terms of comfort, cost, and accessibility.		#* The screening program should be organized in a way that encourages high participation rates. The test should be acceptable to potential participants in terms of comfort, cost, and accessibility.
	# The natural history of the condition, including development from latent to declared disease, should be adequately understood.		# '''The natural history of the condition, including development from latent to declared disease, should be adequately understood.'''
	#* A comprehensive understanding of the disease process is essential, including how the disease progresses from the early or latent stage to symptomatic disease.		#* A comprehensive understanding of the disease process is essential, including how the disease progresses from the early or latent stage to symptomatic disease.
	# There should be an agreed policy on whom to treat as patients.		# '''There should be an agreed policy on whom to treat as patients.'''
	#* Clear guidelines should be established on who will be treated once a disease is detected through screening, considering factors such as stage of the disease, age, and comorbidities.		#* Clear guidelines should be established on who will be treated once a disease is detected through screening, considering factors such as stage of the disease, age, and comorbidities.
	# The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole.		# '''The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole.'''
	#* A cost-benefit analysis should be performed to determine if the benefits of early detection and treatment through the screening program outweigh the costs.		#* A cost-benefit analysis should be performed to determine if the benefits of early detection and treatment through the screening program outweigh the costs.
	# Case-finding should be a continuing process and not a “once and for all” project.		# '''Case-finding should be a continuing process and not a “once and for all” project.'''
	#* Screening should be an ongoing, systematic process rather than a one-off project. There should be a commitment to maintaining the program, with regular intervals for repeated screening.		#* Screening should be an ongoing, systematic process rather than a one-off project. There should be a commitment to maintaining the program, with regular intervals for repeated screening.

← Older revision		Revision as of 04:23, 11 July 2023
Line 5:		Line 5:


	;The condition sought should be an important health problem.		;# The condition sought should be an important health problem.
	: There should be a clear understanding of the epidemiology of the condition, including incidence and prevalence, and the health and economic burden on individuals and society. The condition should be a significant public health problem justifying the investment in a screening program.		: There should be a clear understanding of the epidemiology of the condition, including incidence and prevalence, and the health and economic burden on individuals and society. The condition should be a significant public health problem justifying the investment in a screening program.

	;There should be an accepted treatment for patients with recognized disease.		;# There should be an accepted treatment for patients with recognized disease.
	: If no treatment or intervention is available that changes the course of the disease, or if the treatment is not generally accepted, then early detection might not lead to improved outcomes.		: If no treatment or intervention is available that changes the course of the disease, or if the treatment is not generally accepted, then early detection might not lead to improved outcomes.

	;Facilities for diagnosis and treatment should be available.		;# Facilities for diagnosis and treatment should be available.
	; Prior to starting a screening program, health systems should ensure there are sufficient resources for diagnostic confirmation and treatment of individuals who screen positive, as well as appropriate follow-up.		: Prior to starting a screening program, health systems should ensure there are sufficient resources for diagnostic confirmation and treatment of individuals who screen positive, as well as appropriate follow-up.

	;There should be a recognizable latent or early symptomatic stage.		;# There should be a recognizable latent or early symptomatic stage.
	: This criterion refers to the natural history of the disease. There should be a period during which the disease can be detected before the onset of symptoms, and intervention at this stage should lead to better outcomes.		: This criterion refers to the natural history of the disease. There should be a period during which the disease can be detected before the onset of symptoms, and intervention at this stage should lead to better outcomes.

	;There should be a suitable test or examination.		;# There should be a suitable test or examination.
	: The screening test should be reliable, safe, inexpensive, and valid with high sensitivity and specificity. It should be able to accurately detect the early or latent stage of the disease.		: The screening test should be reliable, safe, inexpensive, and valid with high sensitivity and specificity. It should be able to accurately detect the early or latent stage of the disease.

	;The test should be acceptable to the population.		;# The test should be acceptable to the population.
	: The screening program should be organized in a way that encourages high participation rates. The test should be acceptable to potential participants in terms of comfort, cost, and accessibility.		: The screening program should be organized in a way that encourages high participation rates. The test should be acceptable to potential participants in terms of comfort, cost, and accessibility.

	;The natural history of the condition, including development from latent to declared disease, should be adequately understood.		;# The natural history of the condition, including development from latent to declared disease, should be adequately understood.
	; A comprehensive understanding of the disease process is essential, including how the disease progresses from the early or latent stage to symptomatic disease.		: A comprehensive understanding of the disease process is essential, including how the disease progresses from the early or latent stage to symptomatic disease.

	;There should be an agreed policy on whom to treat as patients.		;# There should be an agreed policy on whom to treat as patients.
	: Clear guidelines should be established on who will be treated once a disease is detected through screening, considering factors such as stage of the disease, age, and comorbidities.		: Clear guidelines should be established on who will be treated once a disease is detected through screening, considering factors such as stage of the disease, age, and comorbidities.

	;The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole.		;# The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be economically balanced in relation to possible expenditure on medical care as a whole.
	: A cost-benefit analysis should be performed to determine if the benefits of early detection and treatment through the screening program outweigh the costs.		: A cost-benefit analysis should be performed to determine if the benefits of early detection and treatment through the screening program outweigh the costs.

	;Case-finding should be a continuing process and not a “once and for all” project.		;# Case-finding should be a continuing process and not a “once and for all” project.
	: Screening should be an ongoing, systematic process rather than a one-off project. There should be a commitment to maintaining the program, with regular intervals for repeated screening.		: Screening should be an ongoing, systematic process rather than a one-off project. There should be a commitment to maintaining the program, with regular intervals for repeated screening.